Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease

Yoshihiro Inamoto, Paul J. Martin, Sophie Paczesny, Laura Tabellini, Amin A. Momin, Christen L. Mumaw, Mary E.D. Flowers, Stephanie J. Lee, Paul A. Carpenter, Barry E. Storer, Samir Hanash, John A. Hansen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (GVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic cell transplantation. To identify prognostic plasma proteins associated with de novo- or quiescent-onset chronic GVHD (cGVHD), we performed a discovery and validation proteomic study. The total study cohort included 167 consecutive patients who had no clinical evidence of GVHD under minimum glucocorticoid administration and had available plasma samples obtained at 80 ± 14 days after transplantation. We first used high-throughput mass spectrometry to screen pooled plasma using 20 cases with subsequent cGVHD and 20 controls without it, and we identified 20 candidate proteins. We then measured 12 of the 20 candidate proteins by ELISA on the same individual samples and identified 4 proteins for further verification (LGALS3BP, CD5L, CD163, and TXN for de novo onset, and LGALS3BP and CD5L for quiescent onset). The verification cohort included 127 remaining patients. The cumulative incidence of de novo-onset cGVHD was higher in patients with higher plasma soluble CD163 concentrations at day 80 than those with lower concentrations (75% versus 40%, P = .018). The cumulative incidence of de novo- or quiescent-onset cGVHD did not differ statistically according to concentrations of the 3 other proteins at day 80. CD163 is a macrophage scavenger receptor and is elevated in oxidative conditions. These results suggest that monocyte or macrophage activation or increased oxidative stress may contribute to the pathogenesis of cGVHD.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Mar 22 2017

Fingerprint

Graft vs Host Disease
Proteins
Scavenger Receptors
Macrophage Activation
Validation Studies
Incidence
Cell Transplantation
Proteomics
Glucocorticoids
Blood Proteins
Monocytes
Mass Spectrometry
Oxidative Stress
Cohort Studies
Transplantation
Enzyme-Linked Immunosorbent Assay
Morbidity
Mortality

Keywords

  • Biomarker discovery
  • CD163
  • Chronic graft-versus-host disease
  • Macrophage

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease. / Inamoto, Yoshihiro; Martin, Paul J.; Paczesny, Sophie; Tabellini, Laura; Momin, Amin A.; Mumaw, Christen L.; Flowers, Mary E.D.; Lee, Stephanie J.; Carpenter, Paul A.; Storer, Barry E.; Hanash, Samir; Hansen, John A.

In: Biology of Blood and Marrow Transplantation, 22.03.2017.

Research output: Contribution to journalArticle

Inamoto, Y, Martin, PJ, Paczesny, S, Tabellini, L, Momin, AA, Mumaw, CL, Flowers, MED, Lee, SJ, Carpenter, PA, Storer, BE, Hanash, S & Hansen, JA 2017, 'Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2017.04.019
Inamoto, Yoshihiro ; Martin, Paul J. ; Paczesny, Sophie ; Tabellini, Laura ; Momin, Amin A. ; Mumaw, Christen L. ; Flowers, Mary E.D. ; Lee, Stephanie J. ; Carpenter, Paul A. ; Storer, Barry E. ; Hanash, Samir ; Hansen, John A. / Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease. In: Biology of Blood and Marrow Transplantation. 2017.
@article{ae1e3883f2db4bc588ecf1f84a18f077,
title = "Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease",
abstract = "Chronic graft-versus-host disease (GVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic cell transplantation. To identify prognostic plasma proteins associated with de novo- or quiescent-onset chronic GVHD (cGVHD), we performed a discovery and validation proteomic study. The total study cohort included 167 consecutive patients who had no clinical evidence of GVHD under minimum glucocorticoid administration and had available plasma samples obtained at 80 ± 14 days after transplantation. We first used high-throughput mass spectrometry to screen pooled plasma using 20 cases with subsequent cGVHD and 20 controls without it, and we identified 20 candidate proteins. We then measured 12 of the 20 candidate proteins by ELISA on the same individual samples and identified 4 proteins for further verification (LGALS3BP, CD5L, CD163, and TXN for de novo onset, and LGALS3BP and CD5L for quiescent onset). The verification cohort included 127 remaining patients. The cumulative incidence of de novo-onset cGVHD was higher in patients with higher plasma soluble CD163 concentrations at day 80 than those with lower concentrations (75{\%} versus 40{\%}, P = .018). The cumulative incidence of de novo- or quiescent-onset cGVHD did not differ statistically according to concentrations of the 3 other proteins at day 80. CD163 is a macrophage scavenger receptor and is elevated in oxidative conditions. These results suggest that monocyte or macrophage activation or increased oxidative stress may contribute to the pathogenesis of cGVHD.",
keywords = "Biomarker discovery, CD163, Chronic graft-versus-host disease, Macrophage",
author = "Yoshihiro Inamoto and Martin, {Paul J.} and Sophie Paczesny and Laura Tabellini and Momin, {Amin A.} and Mumaw, {Christen L.} and Flowers, {Mary E.D.} and Lee, {Stephanie J.} and Carpenter, {Paul A.} and Storer, {Barry E.} and Samir Hanash and Hansen, {John A.}",
year = "2017",
month = "3",
day = "22",
doi = "10.1016/j.bbmt.2017.04.019",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease

AU - Inamoto, Yoshihiro

AU - Martin, Paul J.

AU - Paczesny, Sophie

AU - Tabellini, Laura

AU - Momin, Amin A.

AU - Mumaw, Christen L.

AU - Flowers, Mary E.D.

AU - Lee, Stephanie J.

AU - Carpenter, Paul A.

AU - Storer, Barry E.

AU - Hanash, Samir

AU - Hansen, John A.

PY - 2017/3/22

Y1 - 2017/3/22

N2 - Chronic graft-versus-host disease (GVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic cell transplantation. To identify prognostic plasma proteins associated with de novo- or quiescent-onset chronic GVHD (cGVHD), we performed a discovery and validation proteomic study. The total study cohort included 167 consecutive patients who had no clinical evidence of GVHD under minimum glucocorticoid administration and had available plasma samples obtained at 80 ± 14 days after transplantation. We first used high-throughput mass spectrometry to screen pooled plasma using 20 cases with subsequent cGVHD and 20 controls without it, and we identified 20 candidate proteins. We then measured 12 of the 20 candidate proteins by ELISA on the same individual samples and identified 4 proteins for further verification (LGALS3BP, CD5L, CD163, and TXN for de novo onset, and LGALS3BP and CD5L for quiescent onset). The verification cohort included 127 remaining patients. The cumulative incidence of de novo-onset cGVHD was higher in patients with higher plasma soluble CD163 concentrations at day 80 than those with lower concentrations (75% versus 40%, P = .018). The cumulative incidence of de novo- or quiescent-onset cGVHD did not differ statistically according to concentrations of the 3 other proteins at day 80. CD163 is a macrophage scavenger receptor and is elevated in oxidative conditions. These results suggest that monocyte or macrophage activation or increased oxidative stress may contribute to the pathogenesis of cGVHD.

AB - Chronic graft-versus-host disease (GVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic cell transplantation. To identify prognostic plasma proteins associated with de novo- or quiescent-onset chronic GVHD (cGVHD), we performed a discovery and validation proteomic study. The total study cohort included 167 consecutive patients who had no clinical evidence of GVHD under minimum glucocorticoid administration and had available plasma samples obtained at 80 ± 14 days after transplantation. We first used high-throughput mass spectrometry to screen pooled plasma using 20 cases with subsequent cGVHD and 20 controls without it, and we identified 20 candidate proteins. We then measured 12 of the 20 candidate proteins by ELISA on the same individual samples and identified 4 proteins for further verification (LGALS3BP, CD5L, CD163, and TXN for de novo onset, and LGALS3BP and CD5L for quiescent onset). The verification cohort included 127 remaining patients. The cumulative incidence of de novo-onset cGVHD was higher in patients with higher plasma soluble CD163 concentrations at day 80 than those with lower concentrations (75% versus 40%, P = .018). The cumulative incidence of de novo- or quiescent-onset cGVHD did not differ statistically according to concentrations of the 3 other proteins at day 80. CD163 is a macrophage scavenger receptor and is elevated in oxidative conditions. These results suggest that monocyte or macrophage activation or increased oxidative stress may contribute to the pathogenesis of cGVHD.

KW - Biomarker discovery

KW - CD163

KW - Chronic graft-versus-host disease

KW - Macrophage

UR - http://www.scopus.com/inward/record.url?scp=85019571995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019571995&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.04.019

DO - 10.1016/j.bbmt.2017.04.019

M3 - Article

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -